Epidemiology of infections caused by polymyxin-resistant pathogens

International Journal of Antimicrobial Agents

Volumn 48, Issue 6, 2016, Pages 614-621

  Giamarellou, Helen ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

Chromosomal; Colistin; Gram negatives; mcr 1 gene; Plasmid mediated; Resistance

Indexed keywords

CARBAPENEMASE; COLISTIN; METALLO BETA LACTAMASE; POLYMYXIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CARRIER; BACTERIUM ISOLATION; CARBAPENEMASE GENE; CHINA; CHROMOSOME; DRUG USE; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; GREECE; HOSPITAL; HUMAN; INFECTION RISK; ITALY; KLEBSIELLA PNEUMONIAE; LIVESTOCK; MCR 1 GENE; MEAT; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PLASMID; PREVALENCE; PRIORITY JOURNAL; SOUTHEAST ASIA; SOUTHERN EUROPE; VETERINARY MEDICINE; ANIMAL; ANIMAL HUSBANDRY; ANTIBIOTIC PROPHYLAXIS; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEALTH; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PROCEDURES; VETERINARY;

ANIMAL HUSBANDRY; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, BACTERIAL; GLOBAL HEALTH; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 85001073384     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.09.025     Document Type: Article

References (78)

1. [1] Karaiskos, I., Giamarellou, H., Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15 (2014), 1351–1370.
2. [2] Tzouvelekis, L.S., Markogiannakis, A., Piperaki, E., Souli, M., Daikos, G.L., Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20 (2014), 862–872.
3. [3] Pantelidou, I.M., Galani, I., Georgitsi, M., Daikos, G.L., Giamarellos-Bourboulis, E.J., Interactions of Klebsiella pneumoniae with the innate immune system vary in relation to clone and resistance phenotype. Antimicrob Agents Chemother 59 (2015), 7036–7043.
4. [4] European Centre for Disease Prevention and Control (ECDC), Rapid risk assessment: carbapenem-resistant Enterobacteriaceae. Stockholm, Sweden: ECDC; 14 April; Available from: http://ecdc.europa.eu/en/publications/risk_assessment/Pages/default.aspx, 2016 Accessed 2 November 2016.
5. [5] European Centre for Disease Prevention and Control (ECDC), Consumption of polymyxins (ATC group J01XB) in the hospital sector in Europe, reporting year 2014. ESAC-Net surveillance data. Stockholm, Sweden: ECDC; Available from: http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance-and-consumption/antimicrobial-consumption/esac-net-database/Pages/Antimicrobial-consumption-rates-by-country.aspx, 2014 Accessed 2 November 2016.
6. [6] Antoniadou, A., Kontopidou, F., Poulakou, G., Koratzanis, E., Galani, I., Papadomichelakis, E., et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 59 (2007), 786–790.
7. [7] Marchaim, D., Chopra, T., Pogue, J.M., Perez, F., Hujer, A.M., Rudin, S., et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 55 (2011), 593–599.
8. [8] Kontopidou, F., Plachouras, D., Papadomichelakis, E., Koukos, G., Galani, I., Poulakou, G., et al. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect 17 (2011), E9–11.
9. [9] Ah, Y.M., Kim, A.J., Lee, J.Y., Colistin resistance in Klebsiella pneumoniae. Int J Antimicrob Agents 44 (2014), 8–15.
10. [10] Liu, Y.Y., Wang, Y., Walsh, T.R., Yi, L.X., Zhang, R., Spencer, J., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16 (2016), 161–168.
11. [11] Giani, T., Pini, B., Arena, F., Conte, V., Bracco, S., Migliavacca, R., et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill, 18, 2013.
12. [12] Monaco, M., Giani, T., Raffone, M., Arena, F., Garcia-Fernandez, A., Pollini, S., et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill, 19, 2014.
13. [13] Maltezou, H.C., Kontopidou, F., Dedoukou, X., Katerelos, P., Gourgoulis, G.-M., Tsonou, P., et al. Action plan to combat infections due to carbapenem-resistant, Gram-negative pathogens in acute-care hospitals in Greece. J Glob Antimicrob Resist 2 (2014), 11–16.
14. [14] European Centre for Disease Prevention and Control (ECDC), Antimicrobial resistance surveillance in Europe 2014. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden: ECDC; Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf, 2014 Accessed 2 November 2016.
15. [15] Sader, H.S., Farrell, D.J., Castanheira, M., Flamm, R.K., Jones, R.N., Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother 69 (2014), 2713–2722.
16. [16] European Centre for Disease Prevention and Control (ECDC), Antimicrobial resistance surveillance in Europe 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm, Sweden: ECDC, 2014.
17. KPC-producing Klebsiella pneumoniae in a Greek Hospital. Microb Drug Resist 22 (2016), 392–398.
18. [18] Bradford, P.A., Kazmierczak, K.M., Biedenbach, D.J., Wise, M.G., Hackel, M., Sahm, D.F., Correlation of β-lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program. Antimicrob Agents Chemother 60 (2015), 1385–1392.
19. [19] Hejnar, P., Kolár, M., Hájek, V., Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of β-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc. Acta Univ Palacki Olomuc Fac Med 142 (1999), 73–77.
20. [20] Cai, Y., Chai, D., Wang, R., Liang, B., Bai, N., Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67 (2012), 1607–1615.
21. [21] Oikonomou, O., Sarrou, S., Papagiannitsis, C.C., Georgiadou, S., Mantzarlis, K., Zakynthinos, E., et al. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis, 15, 2015, 559.
22. [22] Gómez-Garcés, J.L., Aracil, B., Gil, Y., Burillo, A., Susceptibility of 228 non-fermenting Gram-negative rods to tigecycline and six other antimicrobial drugs. J Chemother 21 (2009), 267–271.
23. [23] Mezzatesta, M.L., Trovato, G., Gona, F., Nicolosi, V.M., Nicolosi, D., Carattoli, A., et al. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann Clin Microbiol Antimicrob, 7, 2008, 4.
24. [24] Dodrewski, R., Savov, E., Bernards, A.T., van den Barselaar, M., Nordmann, P., van den Broek, P.J., et al. Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital. Clin Microbiol Infect 12 (2006), 1135–1137.
25. [25] Arroyo, L.A., Garcia-Curiel, A., Pachon-Ibanez, M.E., Llanos, A.C., Ruiz, M., Pachón, J., et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 43 (2005), 903–905.
26. [26] Arroyo, L.A., Mateos, I., González, V., Aznar, J., In vitro activities of tigecycline, minocycline, and colistin–tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 53 (2009), 1295–1296.
27. [27] Gales, A.C., Jones, R.N., Sader, H.S., Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 66 (2011), 2070–2074.
28. [28] Ko, K.S., Suh, J.Y., Kwon, K.T., Jung, S.I., Park, K.H., Kang, C.I., et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 60 (2007), 1163–1167.
29. [29] Park, Y.K., Jung, S.I., Park, K.H., Cheong, H.S., Peck, K.R., Song, J.H., et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis 64 (2009), 43–51.
30. [30] Qureshi, Z.A., Hittle, L.E., O'Hara, J.A., Rivera, J.I., Syed, A., Shields, R.K., et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60 (2015), 1295–1303.
31. [31] Li, J., Rayner, C.R., Nation, R.L., Owen, R.J., Spelman, D., Tan, K.E., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50 (2006), 2946–2950.
32. [32] Hawley, J.S., Murray, C.K., Jorgensen, J.H., Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52 (2008), 351–352.
33. [33] Liu, Q., Li, W., Feng, Y., Tao, C., Efficacy and safety of polymyxins for the treatment of Acinetobacter baumannii infection: a systematic review and meta-analysis. PLoS ONE, 9, 2014 e98091.
34. [34] Karaiskos, I., Friberg, L.E., Pontikis, K., Ioannidis, K., Tsagkari, V., Galani, L., et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother 59 (2015), 7240–7248.
35. [35] Schülin, T., In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 49 (2002), 403–406.
36. [36] Sader, H.S., Farrell, D.J., Flamm, R.K., Jones, R.N., Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis 78 (2014), 443–448.
37. [37] Gandra, S., Mojica, N., Klein, E.Y., Ashok, A., Nerurkar, V., Kumari, M., et al. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014. Int J Infect Dis 50 (2016), 75–82.
38. [38] Goli, H.R., Nahaei, M.R., Ahangarzadeh Rezaee, M., Hasani, A., Samadi Kafil, H., Aghazadeh, M., Emergence of colistin resistant Pseudomonas aeruginosa at Tabriz hospitals, Iran. Iran J Microbiol 8 (2016), 62–69.
39. [39] Clausell, A., Garcia-Subirats, M., Pujol, M., Busquets, M.A., Rabanal, F., Cajal, Y., Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J Phys Chem B 111 (2007), 551–563.
40. [40] Raetz, C.R., Reynolds, C.M., Trent, M.S., Bishop, R.E., Lipid A modification systems in Gram-negative bacteria. Annu Rev Biochem 76 (2007), 295–329.
41. [41] Fernández, L., Jenssen, H., Bains, M., Wiegand, I., Gooderham, W.J., Hancock, R.E., The two-component system CprRS senses cationic peptides and triggers adaptive resistance in Pseudomonas aeruginosa independently of ParRS. Antimicrob Agents Chemother 56 (2012), 6212–6222.
42. [42] Olaitan, A.O., Morand, S., Rolain, J.M., Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol, 5, 2014, 643.
43. [43] Wright, M.S., Suzuki, Y., Jones, M.B., Marshall, S.H., Rudin, S.D., van Duin, D., Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob Agents Chemother 59 (2015), 536–543.
44. [44] Matthaiou, D.K., Michalopoulos, A., Rafailidis, P.I., Karageorgopoulos, D.E., Papaioannou, V., Ntani, G., et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case–control study. Crit Care Med 36 (2008), 807–811.
45. [45] Mentzelopoulos, S.D., Pratikaki, M., Platsouka, E., Kraniotaki, H., Zervakis, D., Koutsoukou, A., et al. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med 33 (2007), 1524–1532.
46. [46] Giani, T., Arena, F., Vaggelli, G., Conte, V., Chiarelli, A., Henrici De Angelis, L., et al. Large nosocomial outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae traced to clonal expansion of an mgrB deletion mutant. J Clin Microbiol 53 (2015), 3341–3344.
47. [47] Falcone, M., Russo, A., Iacovelli, A., Restuccia, G., Ceccarelli, G., Giordano, A., et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect 22 (2016), 444–450.
48. [48] Giacobbe, D.R., Del Bono, V., Trecarichi, E.M., De Rosa, F.G., Giannella, M., Bassetti, M., et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control study. Clin Microbiol Infect, 21, 2015, 1106 e1–8.
49. [49] Bassetti, M., Righi, E., SDD and colistin resistance: end of a dream?. Intensive Care Med 40 (2014), 1066–1067.
50. [50] Halaby, T., Al Naiemi, N., Kluytmans, J., van der Palen, J., Vandenbroucke-Grauls, C.M., Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother 57 (2013), 3224–3229.
51. [51] Wittekamp, B.H., Oostdijk, E.A., de Smet, A.M., Bonten, M.J., Colistin and tobramycin resistance during long-term use of selective decontamination strategies in the intensive care unit: a post hoc analysis. Crit Care, 19, 2015, 113.
52. [52] Olaitan, A.O., Morand, S., Rolain, J.M., Emergence of colistin-resistant bacteria in humans without colistin usage: a new worry and cause for vigilance. Int J Antimicrob Agents 47 (2016), 1–3.
53. [53] Napier, B.A., Burd, E.M., Satola, S.W., Cagle, S.M., Ray, S.M., McGann, P., et al. Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii. MBio 4 (2013), e21–13.
54. [54] Kempf, I., Fleury, M.A., Drider, D., Bruneau, M., Sanders, P., Chauvin, C., et al. What do we know about resistance to colistin in Enterobacteriaceae in avian and pig production in Europe?. Int J Antimicrob Agents 42 (2013), 379–383.
55. [55] Skov, R.L., Monnet, D.L., Plasmid-mediated colistin resistance (mcr-1 gene): three months later, the story unfolds. Euro Surveill, 21, 2016, 10.2807/1560-7917.ES.2016.21.9.30155.
56. [56] Nordmann, P., Poirel, L., Plasmid-mediated colistin resistance: an additional antibiotic resistance menace. Clin Microbiol Infect 22 (2016), 398–400.
57. [57] Cannatelli, A., Giani, T., Antonelli, A., Principe, L., Luzzaro, F., Rossolini, G.M., First detection of the mcr-1 colistin resistance gene in Escherichia coli in Italy. Antimicrob Agents Chemother 60 (2016), 3257–3258.
58. [58] Quesada, A., Ugarte-Ruiz, M., Iglesias, M.R., Porrero, M.C., Martínez, R., Florez-Cuadrado, D., et al. Detection of plasmid mediated colistin resistance (MCR-1) in Escherichia coli and Salmonella enterica isolated from poultry and swine in Spain. Res Vet Sci 105 (2016), 134–135.
59. [59] Coetzee, J., Corcoran, C., Prentice, E., Moodley, M., Mendelson, M., Poirel, L., et al. Emergence of plasmid-mediated colistin resistance (MCR-1) among Escherichia coli isolated from South African patients. S Afr Med J 106 (2016), 449–450.
60. [60] Fernandes, M.R., Moura, Q., Sartori, L., Silva, K.C., Cunha, M.P., Esposito, F., et al. Silent dissemination of colistin-resistant Escherichia coli in South America could contribute to the global spread of the mcr-1 gene. Euro Surveill, 21, 2016, 10.2807/1560-7917.ES.2016.21.17.30214.
61. [61] Kuo, S.C., Huang, W.C., Wang, H.Y., Shiau, Y.R., Cheng, M.F., Lauderdale, T.L., Colistin resistance gene mcr-1 in Escherichia coli isolates from humans and retail meats, Taiwan. J Antimicrob Chemother 71 (2016), 2327–2329.
62. [62] Prim, N., Rivera, A., Rodríguez-Navarro, J., Español, M., Turbau, M., Coll, P., et al. Detection of mcr-1 colistin resistance gene in polyclonal Escherichia coli isolates in Barcelona, Spain, 2012 to 2015. Euro Surveill, 21, 2016, 10.2807/1560-7917.ES.2016.21.13.30183.
63. [63] Izdebski, R., Baraniak, A., Bojarska, K., Urbanowicz, P., Fiett, J., Pomorska-Wesołowska, M., Mobile MCR-1-associated resistance to colistin in Poland. J Antimicrob Chemother 71 (2016), 2331–2333.
64. CTX-M on a novel IncF plasmid: first report of MCR-1 in the United States. Antimicrob Agents Chemother 60 (2016), 4420–4421.
65. [65] Sonnevend, Á., Ghazawi, A., Alqahtani, M., Shibl, A., Jamal, W., Hashmey, R., Plasmid-mediated colistin resistance in Escherichia coli from the Arabian Peninsula. Int J Infect Dis 50 (2016), 85–90.
66. NDM-1 in Escherichia coli from Venezuela. Antimicrob Agents Chemother 60 (2016), 6356–6358.
67. [67] Fernandes, M.R., McCulloch, J.A., Vianello, M.A., Moura, Q., Pérez-Chaparro, P.J., Esposito, F., et al. First report of the globally disseminated IncX4 plasmid carrying the mcr-1 gene in a colistin-resistant Escherichia coli sequence type 101 isolate from a human infection in Brazil. Antimicrob Agents Chemother 60 (2016), 6415–6417.
68. [68] Castanheira, M., Griffin, M.A., Deshpande, L.M., Mendes, R.E., Jones, R.N., Flamm, R.K., Detection of MCR-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. Antimicrob Agents Chemother 60 (2016), 5623–5624.
69. [69] Suzuki, S., Ohnishi, M., Kawanishi, M., Akiba, M., Kuroda, M., Investigation of a plasmid genome database for colistin-resistance gene mcr-1. Lancet Infect Dis 16 (2016), 284–285.
70. [70] Haenni, M., Poirel, L., Kieffer, N., Châtre, P., Saras, E., Métayer, V., et al. Co-occurrence of extended spectrum β lactamase and MCR-1 encoding genes on plasmids. Lancet Infect Dis 16 (2016), 281–282.
71. [71] Poirel, L., Kieffer, N., Liassine, N., Thanh, D., Nordmann, P., Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of Escherichia coli. Lancet Infect Dis, 16, 2016, 281.
72. [72] Falgenhauer, L., Waezsada, S.E., Yao, Y., Imirzalioglu, C., Käsbohrer, A., Roesler, U., et al. Colistin resistance gene mcr-1 in extended-spectrum β-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. Lancet Infect Dis 16 (2016), 282–283.
73. [73] Du, H., Chen, L., Tang, Y.W., Kreiswirth, B.N., Emergence of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae. Lancet Infect Dis 16 (2016), 287–288.
74. [74] Dubourg, G., Okdah, L., Le Page, S., Rolain, J.M., Raoult, D., In vitro activity of old antibiotics against highly resistant Gram-negative bacteria. Int J Antimicrob Agents 46 (2015), 718–720.
75. [75] Di Pilato, V., Arena, F., Tascini, C., Cannatelli, A., Henrici De Angelis, L., Fortunato, S., et al. mcr-1.2, a new MCR variant carried on a transferable plasmid from a colistin-resistant KPC carbapenemase-producing Klebsiella pneumoniae strain of sequence type 512. Antimicrob Agents Chemother 60 (2016), 5612–5615.
76. [76] Xavier, B.B., Lammens, C., Ruhal, R., Kumar-Singh, S., Butaye, P., Goossens, H., et al. Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Euro Surveill, 21, 2016, 10.2807/1560-7917.ES.2016.21.27.30280.
77. [77] Giamarellou, H., Galani, L., Baziaka, F., Karaiskos, I., Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 57 (2013), 2388–2390.
78. [78] O'Neil, J., Antimicrobial resistance: tackling a crisis for the future health and wealth of nations. RAND Europe and KPMG; 11 December. Available from: http://amr-review.org/Publications, 2014 Accessed 2 November 2016.